Jiangsu Hengrui Pharmaceuticals Co.,Ltd (SHA:600276)

Market Cap	383.70B +33.7%
Revenue (ttm)	30.98B +19.2%
Net Income	7.47B +37.1%
EPS	1.16 +34.9%
Shares Out	6.62B
PE Ratio	49.87
Forward PE	41.59
Dividend	0.20 (0.34%)
Ex-Dividend Date	May 23, 2025

Volume	31,519,386
Average Volume	56,697,346
Open	57.86
Previous Close	57.86
Day's Range	56.86 - 58.10
52-Week Range	44.20 - 74.04
Beta	0.25
RSI	39.49
Earnings Date	Mar 26, 2026

About SHA:600276

Jiangsu Hengrui Pharmaceuticals Co.,Ltd, a pharmaceutical company, researches, develops, manufactures, and commercializes medicines to address unmet clinical needs in China and internationally. It develops medicines in the areas of oncology, metabolic and cardiovascular, immunological and respiratory, neuroscience, pain management, infectious, respiratory system, hematological, ophthalmology, and autoimmune and other diseases. The company was founded in 1970 and is headquartered in Lianyungang, China.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1970
• Employees: 20,238
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600276

Financial Performance

In 2024, SHA:600276's revenue was 27.98 billion, an increase of 22.63% compared to the previous year's 22.82 billion. Earnings were 6.34 billion, an increase of 47.28%.